Disturbance of Redox Homeostasis in Down Syndrome: Role of Iron Dysmetabolism by Barone, Eugenio et al.
University of Kentucky
UKnowledge
Sanders-Brown Center on Aging Faculty
Publications Aging
1-2018
Disturbance of Redox Homeostasis in Down
Syndrome: Role of Iron Dysmetabolism
Eugenio Barone
Sapienza University of Rome, Italy
Andrea Arena
Sapienza University of Rome, Italy
Elizabeth Head
University of Kentucky, elizabeth.head@uky.edu
D. Allan Butterfield
University of Kentucky, david.butterfield@uky.edu
Marzia Perluigi
Sapienza University of Rome, Italy
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/sbcoa_facpub
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, and the
Neurosciences Commons
This Article is brought to you for free and open access by the Aging at UKnowledge. It has been accepted for inclusion in Sanders-Brown Center on
Aging Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Barone, Eugenio; Arena, Andrea; Head, Elizabeth; Butterfield, D. Allan; and Perluigi, Marzia, "Disturbance of Redox Homeostasis in
Down Syndrome: Role of Iron Dysmetabolism" (2018). Sanders-Brown Center on Aging Faculty Publications. 119.
https://uknowledge.uky.edu/sbcoa_facpub/119
Disturbance of Redox Homeostasis in Down Syndrome: Role of Iron Dysmetabolism
Notes/Citation Information
Published in Free Radical Biology and Medicine, v. 114, p. 84-93.
© 2017 Elsevier Inc. All rights reserved.
This manuscript version is made available under the CC‐BY‐NC‐ND 4.0 license
https://creativecommons.org/licenses/by-nc-nd/4.0/.
The document available for download is the author's post-peer-review final draft of the article.
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.freeradbiomed.2017.07.009
This article is available at UKnowledge: https://uknowledge.uky.edu/sbcoa_facpub/119
Disturbance of redox homeostasis in Down Syndrome: role of 
iron dysmetabolism
Eugenio Barone1,2, Andrea Arena1, Elizabeth Head3,4, D Allan Butterfield3,5, and Marzia 
Perluigi1,*
1Department of Biochemical Sciences, Sapienza University of Rome, Italy
2Universidad Autónoma de Chile, Instituto de Ciencias Biomédicas, Facultad de Salud, Avenida 
Pedro de Valdivia 425, Providencia, Santiago, Chile
3Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506 USA
4Department of Neurology, University of Kentucky, Lexington, KY 40506 USA
5Department of Chemistry, University of Kentucky, Lexington, KY 40506 USA
Abstract
Down syndrome (DS) is the most common genetic form of intellectual disability that leads in the 
majority of cases to development of early-onset Alzheimer-like dementia (AD). The 
neuropathology of DS has several common features with AD including alteration of redox 
homeostasis, mitochondrial deficits, and inflammation among others. Interestingly, some of the 
genes encoded by chromosome 21 are responsible of increased oxidative stress (OS) conditions 
that are further exacerbated by decreased antioxidant defense. Previous studies from our groups 
showed that accumulation of oxidative damage is an early event in DS neurodegeneration and that 
oxidative modifications of selected proteins affects the integrity of the protein degradative systems, 
antioxidant response, neuronal integrity and energy metabolism.
In particular, the current review elaborates recent findings demonstrating the accumulation of 
oxidative damage in DS and we focus attention on specific deregulation of iron metabolism, which 
affects both the central nervous system and the periphery. Iron dysmetabolism is a well-recognized 
factor that contributes to neurodegeneration; thus we opine that better understanding how and to 
what extent the concerted loss of iron dyshomestastis and increased OS occur in DS could provide 
novel insights for the development of therapeutic strategies for the treatment of Alzheimer-like 
dementia.
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Alzheimer-like dementia in Down Syndrome population
Down syndrome (DS) is a congenital birth defect that arises by the complete or partial 
trisomy of Chr21 (trisomy21) and is the most prevailing genetic cause of intellectual 
disability with an incidence of around 1:800 births. The complete triplication of the entire 
Chr21 is not necessary to produce the clinical phenotype of DS individuals; indeed, the 
triplication of just a portion of the distal long arm, described as DS critical region (DSCR), 
has been identified as sufficient for this purpose [1]. The majority (95%) of DS cases are 
caused by non-disjunction of chromosome in meiosis I, during the formation of gametes; 
while 3.2% and 1.8% of residual DS cases are caused, respectively, by translocation and 
mosaicism [2].
The effects of trisomy 21 vary widely from one individual to the other and not every DS 
subject show all the phenotypic features caused by trisomy. Therefore, it is conceivable to 
separate DS features in two types: i) those seen in all patients, for example cognitive decline 
or facial dysmorphology; and ii) those that have variable penetrance, such as the congenital 
heart defect that is observed in 40% of DS cases.
In addition to the chromosomal abnormality, it is believed that additional environmental 
factors could to play an important role in determining different phenotypes. The “gene 
dosage hypothesis” proposes that the overexpression of trisomic genes and their encoded 
proteins is directly responsible for the different phenotypical alterations in DS [3, 4]. The 
amplified developmental instability hypothesis” postulates that the presence of multiple 
phenotypes is caused by the effects of the overexpression of trisomic genes on dysomic 
genes leading to an imbalance in their expression [5]. So far, results obtained by the analysis 
of DS cases and the development of DS mouse models support both hypotheses. Therefore, 
the combination of these two hypothesis indicates a complex scenario in which the 
consistently over- or down-expression of a subset of dosage-sensitive genes lead to different 
phenotypic features.
The main pathological features include seizures, leukemia, vision problems, thyroid 
dysfunction, diabetes and dementia, specifically early onset Alzheimer disease (AD) 
(reviewed in [4]).
In the last decade, DS neuropathology has become an attractive field of research for a 
number of reasons: i) DS can be regarded as a human model of accelerated aging; ii) DS 
allows correlation between genetic defects and pathological phenotypes; iii) and DS 
neuropathology correlates with neurogenesis defects, brain development abnormalities and 
cognitive impairment.
Some of the most consistent and significant alterations in DS involve the brain, which 
demonstrates reduced neuronal content, reduced frontal lobe volume and narrowed superior 
temporal gyrus. DS individuals, after the age of 40, develop a type of dementia that is 
similar to AD, the most common cause of dementia in the elderly population, with 
deposition of senile plaques containing amyloid beta-peptide (Aβ), neurofibrillary tangles 
(NFTs) composed of hyperphoshorylated tau, and cholinergic and serotonergic reduction [6, 
7]. The neurodegenerative process in DS population can be considered a “human model” of 
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pre-clinical, early AD and could contribute to understanding the pathological mechanisms 
involved in the progression to late stage AD. The deposition of Aβ plaques and NTFs are the 
most prominent and detrimental neuropathological changes in AD brain and occur in 
cortical regions that are important in acquiring, storing and retrieving information. These 
regions include temporal lobe structures, such as the hippocampus, as well as frontal and 
parietal regions.
Characteristic features in AD brain are weakening of synaptic networks, neuronal loss and 
increase of brain atrophy [8, 9]. Aβ and tau lesions affect several brain regions in DS, 
including prefrontal cortex, hippocampus, basal ganglia, thalamus, hypothalamus and 
midbrain and are believed to underlie the development of cognitive decline and dementia. 
However, although the depositions of Aβ plaques have been observed in fetus and young DS 
individuals [10–12], signs of dementia are clearly manifested many years later.
Interestingly, a recent study demonstrated elevated amyloid levels that does not reach a 
plateau in the nondemented DS population. The rate of amyloid accumulation differs by pre-
existing amyloid burden and precedes atrophy or dementia in the DS population, similar to 
general AD progression, thus suggesting consistency of the AD pathophysiologic process in 
DS as well as in the general population [13].
The identification and characterization of the genes and proteins encoded on Chr21 is crucial 
to understand the mechanisms by which the chromosomal abnormality could contribute to 
the development of AD in DS individuals as well as in the general population. The entire 
sequence of human Chr21 is now known and there are 233 coding genes, 299 long non-
coding genes (Ensembl release 78) and 29 microRNAs (miRBase release 21) [14]. After 
investigation with Swiss-Prot and analysis with Gene Ontology Annotation, the 207 proteins 
found encoded on Chr 21: i) take part in 87 different biological processes, and 11 proteins 
are involved in signal transduction; ii) have 81 different molecular functions among which 
DNA binding and transcription factor activity are the most prevalent with 15 proteins; iii) 
are localized in 26 different cellular components, nucleus and the plasma membrane with 19 
and 15 proteins, respectively, are the most predominant cellular localizations [4].
Oxidative stress in Down Syndrome
Among putative mechanisms that contribute to the accelerated aging, cognitive and neuronal 
dysfunction in DS, the oxidative stress (OS) hypothesis has been recognized to affect 
neurogenesis and differentiation, connection and survival in the brain [6, 15–17]. Increased 
OS has been implicated in the development and progression of neurodegenerative diseases 
and several studies confirmed the accumulation of oxidative damage in the brains of both 
AD and DS subjects [18–20].
OS is a condition that results from either overproduction of reactive oxygen and nitrogen 
species (ROS/RNS), or by decreased antioxidant response. The presence of elevated fatty 
acids content in the nervous tissue, together with the high aerobic metabolic activity, are 
responsible of the brain susceptibility to undergo oxidative damage [21–23]. Accordingly, a 
strong correlation between higher OS levels and several cellular toxic processes in 
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neurodegenerative conditions has been reported. ROS such as superoxide anion (O2−•), 
hydrogen peroxide (H2O2), and hydroxyl radical (HO•), are generated as by-products of 
aerobic respiration and various other catabolic and anabolic processes [24]. The major 
source of free radicals is the mitochondrial oxidative phosphorylation pathway, in which 
electron leakage from the electron transport chain causes the formation of O2−• that, in turn, 
is converted by mitochondrial-resident MnSOD into H2O2 and O2 [25]. Indeed, dysfnction 
of complex I has been demonstrated to be one of the major responsible of overproduction of 
ROS in skin DS fibroblast isolated from both fetal and adult subjects [26].
In the cytosol, H2O2 can be efficiently removed by antioxidant systems such as catalase 
(CAT), glutathione peroxidase (GPX) and thioredoxin peroxidase.
Interestingly, triplication of several Hsa21 genes such as SOD1, APP, BACH1, Et2, CR, 
S100B among others are believed to be involved in the increased OS levels found in DS 
individuals and in the Ts65Dn mouse model [16].
SOD1 is the gene encoding for the enzyme that catalyzes the conversion of O2−• into H2O2 
in the cytosol. The increase in SOD activity results in the formation of elevated levels of 
H2O2, and is not paralleled by similar elevation of CAT and GPX, thus leading to the 
overproduction of ROS. Accordingly, all DS tissues, in addition to the brain, display an 
altered SOD-1/GPX activity ratio [27] (Figure 1). SOD-1 was found at levels approximately 
50% higher than normal in a variety of DS cells and tissues, including erythrocytes, B and T 
lymphocytes, and fibroblasts. Another major contributor to the OS hypothesis of 
neurodegeneration in DS is the triplication of APP that is thought to have a key role in the 
pathology of AD. However, triplication of APP does not necessarily lead to enhanced 
expression of APP and subsequent Aβ accumulation, but it is strongly linked to Aβ 
deposition in adult life. As expected, in DS individuals, increased APP gene expression 
leads to increased production of Aβ [28, 29], the major component of amyloid plaques that 
accumulate in brain in all DS individuals over 40 years of age. The levels of Aβ(1-42) and 
Aβ(1-40) are higher in DS plasma than controls and the ratio of Aβ42/Aβ40 is lower in DS 
than in controls [29]. In addition, the same group demonstrated that decreasing levels of 
plasma Aβ42, a decline in the Aβ42/Aβ40 ratio, or increasing levels of Aβ40 may be 
putative markers of conversion to AD in adults with DS, possibly reflecting 
compartmentalization of Aβ peptides in the brain. Several studies demonstrated that Aβ is 
associated with the production of ROS [30, 31] (Figure 1), and also induces calcium-
dependent excitotoxicity, impairment of cellular respiration, and alteration of synaptic 
functions associated with learning and memory [32].
Moreover, it is worth to be mentioning that trisomy 21-induced ROS overproduction may 
itself alter APP processing, promoting intracellular accumulation of Aβ [12]. Thus, 
protecting DS brain from ROS may be of therapeutic value, although antioxidant 
supplementation has failed to show efficacy in preventing dementia in this population [33, 
34]. At the same time, overexpression of APP may promote mitochondrial dysfunction 
independently from aberrant Aβ deposition, thus exacerbating OS conditions [22].
Barone et al. Page 4
Free Radic Biol Med. Author manuscript; available in PMC 2019 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Results from our group and others also suggest the involvement of BACH1, encoded on 
Chr21, in the regulation of the antioxidant response in DS. BACH1 is a transcription 
repressor that plays an important role in the regulation of the expression of genes involved in 
the cell stress response. BACH1, under physiologic conditions, forms heterodimers with 
small Maf proteins (i.e., MafK, MafF and MafG), which bind the antioxidant response 
elements (AREs) of DNA, thereby inhibiting the expression of specific proteins (Figure 1). 
By contrast, increased OS levels suppress the function of BACH1 by promoting BACH1 
nuclear export and enhancing the expression of its gene targets. When the intracellular heme 
levels increase, as under pro-oxidant condition, nuclear BACH1 binds heme and dissociates 
from the AREs thus allowing the expression of genes such as: quinone oxidoreductase-1 
(NQO1), glutathione S-transferase (GST), glutamate-cysteine ligase (GCL) and heme 
oxygenase-1 (HO-1). It is likely that upregulation of BACH1 due to trisomy 21 could block 
the induction of antioxidant genes, therefore promoting OS increase in the cell.
OS markers have been found to be elevated in peripheral and CNS specimens of DS patients 
and animal models of the disease. Levels of TBARS, protein carbonyls, and advanced 
glycation end products were increased in the cortex from DS fetal brain compared with 
controls (reviewed in [16]). Accumulation of 8-hydroxy-2-deoxyguanosine, oxidized 
proteins and nitrotyrosine also was observed in the cytoplasm of cerebral neurons in DS 
[35]. At the peripheral level, the amount of isoprostane 8,12-iso-iPF2α, a specific marker of 
lipid peroxidation, is essentially elevated in urine samples from adults with DS [36].
Among different targets, free radical-mediated damage to proteins may be detrimental in 
aging and in age-related neurodegenerative diseases, because in the majority of cases, 
protein oxidation is a non-reversible phenomenon that therefore requires clearance systems 
for removal [37]. Further, the majority products of amino acids oxidation as well as other 
amino acid modifications cannot be directly repaired and must be selectively eliminated to 
prevent the accumulation of damaged, non-functional proteins. Only few enzymes exist for 
repairing oxidized amino acids, such as methione and cysteine. Generally, oxidation of 
proteins could affect protein expression and gene regulation, protein turnover, cell signaling, 
apoptosis, necrosis, etc., eventually leading to loss of cells and function [20].
Proteomics and redox proteomics approach to study DS neuropathology
The field of proteomics has significantly improved due to advances in the accuracy, 
sensitivity and speed of MS and to the expansion of bioinformatics [38]. However, the 
proteomics analysis of a given system is a complex task as the proteome is dynamic and is 
affected by both intrinsic and extrinsic factors [39]. In the last decade, much effort has been 
given to the analysis of protein changes in DS from the fetal stage, in order to identify the 
molecular targets that from one side can be involved in disease progression and on the other 
can be employed as prenatal diagnostic markers [22, 40–42]. Hence, the study of DS 
samples involved the use of different proteomics methods that employ a number of different 
steps for protein separation and identification of the proteins [41].
Gel-based two-dimensional electrophoresis (2DE) has been widely used in the analysis of 
both human brain samples and biofluids, becoming since its introduction the method of 
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choice to perform differential protein expression analysis. The post-gel detection is achieved 
by the use of specific gel stains, which allow, by specialized software for image analysis, the 
matching and differential quantitation of gel spots. Target spots are excised from the gels 
and digested to peptides by proteolytic enzymes. Individual resolved spots are then 
sequentially analyzed by matrix assisted laser desorption/ionization time-of-flight (MALDI-
TOF) MS or electrospray ionization tandem mass spectrometry (ESI-MS/MS) [38]. A 
further refinement of 2DE proteomics is represented by DIGE that uses the labeling of 
different protein mixture with specific fluorescent dyes, prior to sample separation [43].
Gel-free proteomics techniques allow the identification of proteins in complex mixtures 
using a combination of HPLC and MS. Gel-free analyses are commonly used on a 
standardized platform to compare proteome differences corresponding to disease 
phenotypes, molecular characteristics and responses to stimuli [44]. In addition, gel-free 
proteomics analyses are highly applied to the analysis of human biofluids for the 
quantitation of potential diagnostic markers. Among others, gel-free techniques applied to 
DS include, isotope-coded affinity tag (ICAT) and isobaric tags for relative and absolute 
quantitation (iTRAQ), which couple specific mass-tagging techniques and 2D LC-FT-
Orbitrap-MS, multidimensional protein identification technology (MudiPIT) that consists of 
a 2D-chromatographic separation by at least two orthogonal combinations prior to a ESI/MS 
identification process, and surface-enhanced laser desorption/ionization (SELDI), by which 
proteins of interest are bound to a specific surface before MS analysis by time-of-flight 
(TOF) mass spectrometry [43].
Since OS is an early event in the development and progression of DS neuropathology, our 
laboratory and others focused on the identification of specific brain target of oxidative 
damage that may contribute to the neurodegenerative process and also to establish a direct 
link between tissue specific oxidation and systemic oxidative damage [21, 22, 40, 41, 45, 
46]. These studies took advantage of the use of a redox proteomics approach that is 
specifically dedicated to analysing irreversible oxidative modifications of proteins. The 
redox proteomics approach couples 2DE with immunochemical detection of oxidized 
proteins, followed by MS for protein identification. Proteins containing reactive carbonyl 
groups/3-NT/HNE are detected individually by 2D-western blot analysis using antibodies 
that recognize a specific oxidative modification. The resulting gels and blots are analyzed by 
imaging software to obtain the differential protein oxidation (normalized on protein 
expression) between samples from the different conditions [38, 41].
The application of proteomics platforms in the past years led to the identification of several 
proteins whose alterations may play a crucial role in the development of DS [22]. The first 
proteomics studies were performed, in early 2000 by Lubec and co-workers employing 2DE 
separation on human fetal brain samples from DS subjects compared to age-matched 
controls. Most of the proteins found to be differentially expressed possess a structural role, 
suggesting the alteration of brain development process during DS, consistent with 
characteristic DS phenotypes [47]. Subsequent studies from the same laboratory led to the 
identification of proteins involved in energy metabolism and synaptic plasticity, known to be 
dysfunctional in DS [48–51]. Cenini and co-workers [52] analyzed the frontal cortex of DS 
subjects with or without significant AD pathology in comparison with age-matched controls. 
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In this study, the alteration of common pathways between DS and AD pathology including 
energy metabolism, antioxidant response and proteostasis network have emerged [52].
Besides proteomics studies of human brain, the analysis of brain proteome from mouse 
models of DS also has been also performed in the last decade. In 2004 Kadota et al. 
performed a 2-DE proteomics on TT2F (TT2F/hChr21) mouse embryonal stem cells 
identifying the alterations of structural proteins, heat shock/stress proteins, degradation 
proteins and enzymes for energy and macromolecular metabolism [53]. Those results were 
consistent with human data, supporting once again the involvement of the proteostasis 
network and energy metabolism in the altered development of DS brain. In addition, the 
Lubec group in 2006 [54] analyzed the quantitative variations of proteins in the 141G6 
mouse model of DS, and Wang et al. [55], performed an iTRAQ proteomic study on 
embryonic stem cells from the Tc1 mice, both demonstrating a high correlation between 
expression differences occurring in mouse models of DS and human DS tissue. In 2014 
Ishihara and colleagues found that a dysregulation of protein expression is associated with 
abnormalities during embryonic life in Ts1Cje mice [56].
In parallel to the proteomics analysis of human and mouse models brain samples of DS, 
several groups investigated the alterations of proteome from biofluids [amniotic fluid (AF) 
and plasma from mothers carrying DS fetus and plasma and saliva from DS subjects] with 
the aim to understand the mechanisms involved in DS development and to recognize 
putative markers for prenatal diagnosis. Tsangaris et al. performed initial studies on 
biofluids in 2006 on amniocytes isolated from AF from mothers carrying a DS fetus [57] 
and identified proteins differentially expressed in DS pregnancies that may be involved in 
DS fetal alterations. Other groups performed further studies on AF or amniocytes from DS 
pregnancies, by LC-ESI-MS/MS and SILAC techniques, confirming that the protein profile 
is altered in the AF from DS cases and obtaining reproducible data that may be employed as 
potential diagnostic tools [58, 59].
Moreover, a number of different studies were also conducted on maternal plasma/serum of 
DS pregnancies employing a wide-range of proteomics techniques including iTRAQ, single-
reaction-monitoring (SRM) tandem mass spectrometry-based assay, MuDipit, 2D-DIGE, 
SELDI-TOF and 2DE approaches [60–67]. These studies identified the alteration of several 
maternal plasma-resident proteins during DS gestations that correlate with altered DS 
development and might represent non-invasive diagnostic markers of DS pathology. The 
candidate serum biomarker proteins detected can be categorized into three major functional 
groups: protease inhibitors, acute-phase response proteins, and serum carrier proteins. Many 
of the proteins identified have been previously implicated as playing a role in developmental 
disorders and DS
Accumulating evidence has demonstrated a major role of OS in DS clinical outcomes [16, 
40]. Our laboratory applied redox proteomics to shed light into the molecular pathways 
perturbed by OS, which may play a key role in the neurodegenerative phenomena. In 2012, 
we investigated protein carbonylation levels in young DS (average 24ys) compared to 
healthy subjects obtaining data about specific targets of protein oxidation and their potential 
contribution to the neuropathology [46]. We found increased carbonylation of six proteins 
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identified by MS: ubiquitin carboxy-terminal hydrolase L1 (UCH-L1); cathepsin D; 78-kDa 
glucose-regulated protein 78; V0-type proton ATPase subunit B, brain isoform; glial 
fibrillary acidic protein; and succinyl CoA:3-ketoacid-coenzyme A transferase 1 
mitochondrial. Interestingly, the majority of oxidized proteins, including glucose-regulated 
protein 78; UCH-L1; cathespin D; V0-type proton ATPase subunit B, brain isoform; and 
glial fibrillary acidic protein, are members of the intracellular quality-control system [68, 
69]. We suggest that chronic exposure to OS leads to the impairment of the systems, 
ubiquitin proteasome system (UPS) and the autophagy lysosome system (ALS), involved in 
the removal of unfolded/misfolded proteins and toxic protein aggregates [70–72]. In support 
to this hypothesis, we analyzed proteasome activity and autophagic flux in DS brain 
samples, demonstrating the reduced functionality of both these degradative pathways [46]. 
Thus, it is reasonable to suggest a close relationship between OS and protein misfolding in 
DS brain, implying that these events might be central for the progression of AD-like 
neuropathology in DS subjects.
Since increased lipid peroxidation is one of the main events causing redox imbalance in 
neurodegenerative diseases [73], we employed a redox proteomics approach to identify 
specific targets of 4-hydroxynonenal (HNE) modifications in the frontal cortex from DS 
cases, prior and after development of AD pathology [21]. All the identified proteins are 
involved in in intracellular quality control systems (PQC), cytoskeleton network, energy 
metabolism, and antioxidant response. Overall, our results demonstrate that oxidative 
damage is an early event in DS, and dysfunction of PQC may be critical to make neurons 
more vulnerable to oxidative damage that, once accumulates, contributes to the 
neurodegenerative process. Further, considering that the majority of proteins have been 
already demonstrated to be oxidized in AD brain, our results strongly support the notion that 
aberrant protein oxidation in DS may contribute to AD development [16, 41].
In agreement with our results, previous studies by Ishihara et al. [100] on primary cultured 
astrocytes and neurons from the Ts1Cje mouse model identified by redox proteomics target 
proteins that were modified by two lipid peroxidation derived products, 3- hydroperoxy-9Z,
11E-octadecadienoic acid (13-HPODE), and 4-HNE [74]. Authors found eight proteins in 
total as putative 13-HPODE- and 4-HNE-modified proteins: ATP synthase mitochondrial F1 
complex b-subunit, a- and g-enolase, triosephosphate isomerase 1, neurofilament light 
polypeptide, a-internexin,, peroxiredoxin 6, phosphoglycerate kinase 1 and TPI1. The 
proteins identified were classified into three categories according to their function, proteins 
involved in ATP synthesis, proteins part of the neuronal cytoskeleton, and antioxidant 
enzymes. These results are consistent with increased lipid peroxidation [52], decreased ATP 
content, depletion of antioxidants and aberrant cytoskeletal rearrangement occurring in DS 
and AD [16, 53], suggesting that these modifications could lead to neurodegeneration and to 
reduced cognitive performance. In addition, further studies in DS brain and in Ts65Dn mice 
brain supported the role of BACH1 in the control of HO-1, one of the main components of 
the heme degradation pathway with a powerful antioxidant function [75]. In particular, 
increased BACH1 levels, as result of HSA21 trisomy, leads to the dysregulation of HO-1, 
which, in turn, contributes to the early increase of oxidative stress in DS and provide a 
potential mechanistic explanation for increased protein carbonyls and protein-bound HNE in 
DS [21, 75].
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In recent years, an increasing number of studies have been focused into establishing a direct 
link between tissue-specific oxidation and the oxidative damage of protein components of 
biofluids, since biofluids represents a valid source of information on pathology onset and 
progression in living patients [44]. Correlations between total levels of oxidation markers in 
human brain and biofluids, such as amniotic fluids or plasma have been reported in DS 
pregnancies [40]. Our laboratory contributed to the analysis of AF in DS pregnancies 
evaluating a set of oxidative stress biomarkers that could demonstrate the early occurrence of 
oxidative damage since the fetal stage [45]. Accordingly, we measured specific targets of 
protein carbonylation identifying specific proteins that showed increased oxidation in AF 
from mother carrying DS fetuses compared with healthy controls. The proteins identified by 
redox proteomics are involved in iron homeostasis (ceruloplasmin and transferin), lipid 
metabolism (zinc-a2- glycoprotein, retinol-binding protein 4 and apolipoprotein A1) and 
inflammation (complement C9, a-1B-glycoprotein, collagen a-1V chain). We suggest that 
the increased oxidation of specific proteins could correlate with some characteristic features 
of DS, including early aging, cognitive impairment and also increased risk for cancer and 
immunodeficiency [16]. Our study further demonstrates that OS occurs early in the 
pathogenesis of DS and might play a crucial role in the severity of DS phenotypes. Some of 
the results obtained by redox proteomics are further described in the following section, with 
particular emphasis on iron dysmetabolism.
Iron dysmetabolism in Down Syndrome
Redox proteomics studies from our group showing that both ceruloplasmin (Cp) and 
transferrin (Tf) were oxidatively modified in AF from women carrying DS pregnancy, which 
possibly resulted in impaired functionality, suggested a link between increased oxidative 
stress levels and the defects of iron metabolism in DS [45].
In mammals iron is an important cofactor for several enzymes. Heme iron, in particular, is 
involved in the regulation of various cellular functions, such as respiration, proliferation, and 
differentiation [76]. Iron also modulates specific brain functions by increasing the release 
and turnover of dopamine and other neurotransmitters [77]. The brain is arguably the most 
metabolically active organ in the body and its internal concentration of iron is exceptionally 
high particularly during the phases of neurodevelopment due to iron’s role in 
myelinogenesis [78]. Indeed, a lack of iron prevents the construction of neural connections 
and the synthesis of neurotransmitters, including dopamine, and leads to insufficient energy 
for a rapidly growing organ [79]. In contrast, excessive amounts of iron can trigger the 
formation of highly toxic oxygen radicals through Fenton reaction, which cause protein 
oxidation, lipid peroxidation and DNA damage finally compromising cell viability and 
promoting programmed cell death [77, 80, 81]. These events are characteristic of 
neurodegenerative processes [82].
Iron deficiency anemia in infants, which is estimated to affect 3% of those aged <6 months, 
contributes to a range of neurological disorders and manifests clinically as cognitive, motor 
and social impairments [83–85]. Similarly, although less evidence is available, high levels of 
redox-active iron in the brain have been associated with neurodegenerative disorders, most 
notably Parkinson and AD, yet a gradual increase in brain iron seems to be a feature of 
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normal ageing [86]. Increased brain iron levels might result from intake of infant formula 
that is excessively fortified with iron, thereby altering the trajectory of brain iron uptake and 
amplifying the risk of iron-associated neurodegeneration in later life [86]. Accumulating 
evidence also suggests that impaired iron homeostasis is an early event in AD progression. 
Iron dyshomeostasis leads to a loss of function in several enzymes requiring iron as a 
cofactor, the formation of toxic oxidative species, and the elevated production of beta-
amyloid proteins [87].
With regard to DS pathology, the role of iron has not been clarified. Indeed, a lack of critical 
information especially in the brain, as in the case for AD subjects, renders the field still 
obscure but simultaneously fascinating. The evaluation of iron or iron-associated proteins 
levels in circulating fluids, however, suggests that iron metabolism dysregulation occurs in 
DS subjects. In particular, the main outcomes are represented by a reduction of both total 
iron and Tf levels [88–93].
According to a recent paper, DS patients show increased levels of serum ferritin but 
decreased levels of Tf. Furthermore, despite a slight reduction of total iron content, 
increased levels of free redox-active iron in both plasma and erythrocytes were found [90]. 
In addition, increased iron levels were significantly associated with increased lipid 
peroxidation products such as F2-isoprostane and a worsening of cognitive functions [90]. In 
agreement, a previous study comparing DS and DS/AD subjects showed increased plasma 
ferritin concentration in DS/AD, and the authors proposed that the onset of AD-like 
dementia in DS may possibly be related to the increased uptake and deposition of iron 
following alteration in plasma iron transport [91].
The mean corpuscular volume of erythrocytes in persons with DS is larger than normal in 
the absence of anemia. Red blood cell survival half time seems to be substantially shorter 
than normal in many of these patients. These findings thus suggest that erythrocytes have a 
younger mean age in persons with DS. The increased red blood cell turnover in this 
population may indicate an accelerated aging process of red blood cells and can contribute to 
the increase of redox-active iron in blood whether not compensated by functioning transport 
or storage [89].
The link between peripheral and central iron level regulation is something still under 
investigation, and with regard to the role of iron either in DS brain development or in DS-
associated neuropathology, only a few papers exists. In particular, the oxidative impairment 
of proteins involved in iron metabolism found by redox proteomics analyses was helpful in 
understanding the link among oxidative stress, iron dysmetabolism and neurological deficits.
Iron is mainly absorbed in the duodenum and upper jejunum. The uptake of nutritional iron 
involves reduction of Fe3+ in the intestinal lumen by ferric reductases [such as Dcytb 
(duodenal cytochrome b)] and the subsequent transport of Fe2+ across the apical membrane 
of enterocytes by a transporter protein called divalent metal transporter 1 (DMT1). Then, 
iron within the enterocyte is released via ferroportin into the bloodstream [94]. The 
ferroportin-mediated efflux of Fe2+ is coupled by its re-oxidation to Fe3+, catalysed by the 
membrane-bound ferroxidase such as hephaestin its plasma homologue C) [95] (Figure 2).
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Cp is a glycoprotein characterized as a multicopper ferroxidase, due to the fact that Cp 
contains 95% of the copper in the plasma. The essential role of the ferroxidase activity of Cp 
in iron release from cells was attributed to facilitation of loading of the metal ion onto 
transferrin, which only binds Fe3+. However, a new molecular connection between Cp and 
ferroportin has been established by the finding that ferroxidase activity is required to 
stabilize ferroportin at the cell surface. Ferroxidase-active Cp stabilizes ferroportin at the 
plasma membrane supporting iron export; on the other hand, the absence of Cp or the 
presence of an inactive Cp lead to degradation of ferroportin in specific cell types [96].
To note, in the brain, Cp is expressed as a glycosylphosphatidylinositol (GPI)-linked form in 
astrocytes [97], where Cp is the only existing ferroxidase [98]. In the absence of Cp activity, 
the ferrous iron that enters the CNS cannot be oxidized and is internalized in large amount, 
through a transferrin-independent, non-regulated pathway [99]. The excess import of iron, 
associated to its export inability due to ferroportin malfunction in the absence of Cp, leads to 
the remarkable accumulation of iron within astrocytes observed in neurodenegerative 
diseases [100]. Thus, it is reasonable to think that iron sequestration by astrocytes may 
induce iron deficiency and death in neurons, which are astrocyte-depended for iron 
acquisition [98, 100].
In the bloodstream, iron is transported bound to Tf, a plasma homodimeric beta-globulin that 
binds two ferric iron ions with exceedingly high affinity and maintains Fe3+ in a redox-inert 
state ready to be delivered into tissues [101] (Figure 1). Soluble Tf-Fe complexes are 
recognized by transferrin receptor 1 (TfR1) and 2 (TfR2) [102], two transmembrane 
disulfide-linked glycoproteins encoded by distinct genes sharing 45% homology. The 
affinity of TfR2 for diferric Tf is 30 times lower to that of TfR1, suggesting that the 
contribution of TfR2 to intracellular Fe uptake is not as critical compared to TfR1 [103].
Following binding of Fe3 to TfRs, the TfR-Tf-Fe3+ complexes are internalized within the 
cell by endosomal recycling vesicles. Endosomal Fe3+ is then reduced into Fe2+ by 
metalloreductases and released inside the cell upon endosome acidification, while the TfR-
Tf complex is recycled to the plasma membrane. Here, Tf dissociates from TfR, and is used 
to repeat the cycle [104, 105]. Meanwhile, cytoplasmic Fe2+ is transported to the 
mitochondria where it takes part in the biosynthesis of heme, which is the prosthetic group 
of several proteins including globins and cytochromes [105]. Indeed, iron incorporation into 
heme moieties, other than its importance for the maintenance of globins and cytochromes 
biological functions, represents one of the highly conserved evolutionary mechanisms 
through which Fe2+ toxicity is limited [105].
When intracellular labile Fe increases above a certain threshold level, its pro-oxidant activity 
must be controlled to avoid cytotoxicity. This aspect is mainly regulated by ferritins 
complexes. Ferritin is a protein complex formed by a 24-subunit multimer – a combination 
of ferritin heavy (FTH1) and light (FTL) chains – that, thanks to its ferroxidase activity, first 
converts Fe2+ into Fe3+ and then safely concentrates intracellular iron in a mineralized, 
redox-inactive form for later use (reviewed in [105, 106]). Notably, ferritin-bound iron 
cannot be utilized by the cell. Consequently, iron must be released from ferritin to be 
biologically useful, usually through lysosomal degradation of ferritin [105, 106]. Ferritin 
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protein turnover is a constant process in cells. While the rate of ferritin degradation appears 
to be the same in iron-deficient and iron-replete conditions, the delivery mechanism of 
ferritin to lysosomes seems to be different: autophagy is responsible for delivering ferritin to 
the lysosome during iron deficiency, whereas a non-autophagic pathway dominates during 
iron sufficiency [106].
Defects of iron metabolism in DS appear early during pregnancy. Changes in AF represent a 
reliable index of the physiological condition of the fetus. The biochemical composition of 
AF, routinely used for prenatal diagnosis, is modified throughout pregnancy and its protein 
profile reflects both physiological and pathological changes affecting the fetus and the 
mother [107].
Evaluation of iron levels in AF revealed a significant increase of the catalytic Fe2+ form 
levels in mothers carrying DS fetuses, thus suggesting that Fe2+ can be one of the markers of 
a DS pregnancy [108]. Indeed, high catalytic Fe2+ may result in additional oxidative stress in 
DS-carrying mothers. Therefore, removing excess catalytic iron in amniotic fluid may 
possibly help to decrease the oxidative stress in DS pregnancies and to improve fetal 
prognosis [108].
In agreement with the above sentences, the evaluation of protein carbonyls and HNE-bound 
protein adducts were significantly increased in AF from women carrying DS fetuses with 
respect to AF from women carrying normal foetuses, indicating that both protein and lipid 
peroxidation pathways were enhanced even at the fetal stage in DS [45]. Further, we showed 
by redox proteomics that both Cp and Tf undergo oxidative modifications in AF, which 
impair their functionality [45]. The ferroxidase activity confers Cp with a relevant 
antioxidant power and a significant role in iron homeostasis because ferrous ions, entering 
Fenton reactions, take part in an OS cascade [109]. Although fundamental for normal brain 
activity, Fe2+ may induce neuronal injury by catalyzing the conversion of hydrogen peroxide 
into highly reactive hydroxyl free radical. During exposure to OS, it has been suggested that 
substantial Cp inactivation may occur and free copper ions could be released [110, 111]. 
Furthermore, as explained above, Cp is required for ferroportin stabilization and correct 
functioning. In this scenario, the oxidative-induced impairment of Cp could contribute to 
accumulation of Fe2+ in astrocytes [100] and lead to neuronal damage. Therefore, impaired 
Cp may cause the propagation of free radical-mediated damage to other macromolecules 
upon exposure to OS.
Coupled to Cp, the observed oxidation of Tf in AF from women carrying DS fetuses [45] 
clearly suggest the disruption of iron metabolism early in DS. In fact, reduced Fe2+ 
oxidation to Fe3+ (mediated by Cp) and its further transport (mediated by Tf) might be 
responsible of impaired Fe storage, which possibly initiates multiple redox reactions that 
damage living cells via various pathways, resulting in an exacerbated OS condition that 
contributes to the development of deleterious DS phenotypes. Defective Tf, could also be 
implicated in a reduction of iron flux to the brain, promoting a condition of iron deficiency 
that frequently results in hypomyelination [84, 112]. Iron deficiency, can result in cognitive 
and motor impairments that last throughout life. In addition, impairment of Tf, also could 
impact the synthesis of the heme moiety, which is an essential component of several 
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proteins. Indeed, Tf is taken up by neurons through TfR1-mediated endocytosis, and, as 
noted above, diferric-Tf mediated transport provides the predominant source of iron for 
neurons [113].
As discussed previously, iron is an essential part of the prosthetic heme, and most of the iron 
provided by diet is used in heme biosynthesis and loaded into nascent hemoglobin or 
cytochromes [105]. Dietary Fe can also be extracted from heme, which involves most 
probably the catabolism of heme by the enzyme HO, allowing for Fe extraction and 
subsequent transport (Figure 2). Recycling of Fe2+ extracted from the prosthetic heme 
groups is therefore essential to maintain Fe homeostasis [105].
Two HO isoforms exist: an inducible form, named HO-1 and the constitutive one, named 
HO-2. HO-1 and HO-2 catalyze the same reaction, namely the transformation of iron-
protoporphyrin-IX-alpha (heme) into equimolar amount of Fe2+, carbon monoxide (CO), 
and biliverdin-IX-alpha [114]. However, they seem to play different roles in protecting 
tissues against injuries [115]. The most convincing hypothesis suggests that controlled HO-1 
induction plays a pivotal role in the earliest stages of cellular responses to tissue damage 
(oxidative stress, inflammation, heat shock), whereas HO-2 is constitutively expressed and is 
primarily involved in maintaining cell heme homeostasis [115–118].
In DS brain, despite increased OS levels, no changes in HO-1 protein levels has been 
observed in young subjects, whereas increased levels characterize adult DS subjects 
undergoing AD-like neurodegeneration. Interestingly, increased of HO-1 in DS/AD subjects 
is not comparable with that observed in AD subjects. This phenomenon seems likely linked 
to the trisomy of chr21, which encodes for the nuclear repressor of HO-1 gene, BACH1 [75].
In terms of iron metabolism, repression of HO-1 in DS would reduce the extent of Fe 
extraction from heme, which coupled with impaired transport and storage, might possibly 
represent an additional mechanism contributing to neurodegeneration. Indeed, heme is able 
to promote programmed cell death in response to proinflamamtory stimuli [119–121]. This 
deleterious effect is driven by Fe [122], although it is not clear if Fe must be released from 
heme to become cytotoxic or whether cytotoxicity can be exerted also by Fe within the 
context of the protoporphyrin ring of heme or both [123]. Considering that DS brain shows a 
marked pro-inflammatory state [124], this phenomenon could represent a conceivable 
mechanism occurring in DS.
Although no additional evidence is available with regard to the functioning of proteins 
belonging to iron metabolism in DS brain, there is an observation coming out from redox 
proteomics analyses, which could be further explored to shed light on the iron homeostasis 
in the CNS in DS. Indeed, oxidation of V0-type proton ATPase [46] as well as its poly-
ubiquitinylation [42] were increased in DS brain. This proton pump is essential for 
acidification of vescicles in the endocytic pathway, and therefore the oxidation of the V0-
ATPase pump could lead to dysfunction of autophagy. Mutation of ATPase genes is a well-
recognized risk factor for autophagy related neurodegenerative diseases [125, 126]. It is 
reasonable to speculate that once oxidized V0-ATPase has altered ability to regulate 
intracellular pH thus affecting proper endosomes/lysosomes functionality and autophagy, as 
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was previously seen in a PD model [127]. Since Fe is extracted from TfR/Tf-Fe complexes 
through acidification of the endolysosomal compartment [105], alteration of the endosome 
environment could further contribute to iron dysregulation in the brain.
In a similar manner heme complexes converges at the endolysosomal compartment, where 
heme is extracted [128, 129]. By this reason, reduced heme catabolism because of BACH1-
related repression of HO-1 and the hypothesized reduction of heme extraction due to 
impairment of endosomal acidification, would favour heme accumulation and its associated 
neurotoxic effects [119–121].
Finally, relevant for DS, in a previous study it has been shown that APP possesses 
ferroxidase activity mediated by a conserved H-ferritin-like active site, which is inhibited 
specifically by Zn2+ [130]. Indeed, like Cp, APP: (1) catalytically oxidizes Fe2+; (2) loads 
Fe3+ into transferrin; and (3) has a major interaction with ferroportin [130]. Ablation of APP 
in primary neurons induces marked iron retention. Furthermore, unlike normal mice, APP−/− 
mice are vulnerable to dietary iron exposure, which causes Fe2+ accumulation and OS in 
cortical neurons. Paralleling iron accumulation, APP ferroxidase activity in AD post-mortem 
neocortex is inhibited by endogenous Zn2+, which has been demonstrated to originate from 
Zn2+-laden amyloid aggregates and correlates with Aβ burden [130]. Unfortunately, the role 
of Zn in DS brain is yet to be investigated. However, because DS is characterized by APP 
overexpression and due to the similarity between DS and AD neuropathology, it is 
conceivable that a similar mechanism could occur in DS brain, thus leading to brain iron 
dys-homeostasis.
Concluding remarks
The role of OS in neurodegeneration is well recognized, but intriguingly, we suggest that DS 
represents a special case of genetically encoded OS. Indeed, there are a number of trisomic 
genes, that directly or indirectly affects ROS levels, either by causing increased ROS 
production and decreasing the antioxidant response. This picture might be revisited in light 
few recent evidences suggesting the role of iron dysregulation in DS neuropathology. 
Accordingly, dysregulation of iron metabolism associated with OS and cellular damage is 
viewed as a common event in several neurodegenerative disorders. Iron dyshomeostasis 
leads to a loss of function in several enzymes requiring iron as a cofactor, the formation of 
toxic oxidative species, and the elevated production of beta-amyloid proteins among other 
mechanism of neurotoxicity.
However, the molecular mechanisms linking iron dysregulation to neurodegeneration in DS 
are still poorly understood mainly for paucity of published data and additional research is 
required.
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Figure 1. Trisomy 21-induced oxidative stress
Schematic representation of a sub set of trisomic genes that are associate dwith increased 
oxidative stress (OS) conditions. In detail, SOD1, APP and BACH1 are the triplicated genes 
that are discussed in the review. SOD1 encodes for the enzyme superoxide dismutase; APP 
fort the amyloid precursor protein; and BACH1 for the transcription repressor BACH1 that 
bind to the antioxidant response elements (AREs) of DNA thus suppressing the induction of 
HO-1 and other antioxidant proteins.
CAT=catalase; GPX= glutathione peroxidase; HO-1=heme oxygenase 1; BVR-A= biliverdin 
reductase A;
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Figure 2. Schematic overview of the main iron metabolic pathways possibly involved in Down 
Syndrome neurodegeneration
In blue, proteins found to be altered in Down Syndrome. APP, amyloid precursor protein; 
BBB, blood brain barrier; CO, carbon monoxide; TFR-1/2, transferrin receptor-1/2;
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